uniQure NV QURE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
-
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
-
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
-
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
-
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
-
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
-
uniQure to Announce Second Quarter 2026 Financial Results
-
UniQure Shares Soar on Go-to-Market Plan
Trading Information
- Previous Close Price
- $22.52
- Day Range
- $21.70–22.68
- 52-Week Range
- $8.73–71.50
- Bid/Ask
- $21.55 / $22.87
- Shares Outstanding
- 69.37M
- Market Cap
- $1.51B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 72.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 221
- Website
- https://www.uniqure.com
Valuation
|
Metric
|
QURE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.66 |
Price/Sales | 72.88 |
Price/Cash Flow | — |
Price/Earnings
QURE
Financial Strength
|
Metric
|
QURE
|
|---|---|
Quick Ratio | 9.79 |
Current Ratio | 10.01 |
Interest Coverage | −3.44 |
Quick Ratio
QURE
Profitability
|
Metric
|
QURE
|
|---|---|
Return on Assets (Normalized) | −28.44% |
Return on Equity (Normalized) | −128.77% |
Return on Invested Capital (Normalized) | −82.52% |
Return on Assets
QURE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G<@&<ZQ | LOCK|@#<XT | $127B | |||
| Moderna Inc
MRNA
| LOCK|<>qGd#? | LOCK|rZ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|d?Q>@# | LOCK|tsp&k | $81B | |||
| argenx SE ADR
ARGX
| LOCK|&><?ln> | LOCK|^? | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Zv&$@V< | LOCK|&x | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|xYb%c$J | LOCK|?@jL$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|r<lxl%Px | LOCK|JFC@ | $27B | |||
| Incyte Corp
INCY
| LOCK|T?$JJ$? | LOCK|R## | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|HYx%G%$ | LOCK|<< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#&Qk&m | LOCK|vj | $14B |
United States